Edgewise Therapeutics (EWTX) Competitors $15.45 +0.19 (+1.25%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$15.45 0.00 (0.00%) As of 06/10/2025 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EWTX vs. GRFS, TLX, TGTX, NUVL, LEGN, LNTH, AXSM, ADMA, PCVX, and MRUSShould you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Grifols (GRFS), Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), Nuvalent (NUVL), Legend Biotech (LEGN), Lantheus (LNTH), Axsome Therapeutics (AXSM), ADMA Biologics (ADMA), Vaxcyte (PCVX), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry. Edgewise Therapeutics vs. Grifols Telix Pharmaceuticals Limited American Depositary Shares TG Therapeutics Nuvalent Legend Biotech Lantheus Axsome Therapeutics ADMA Biologics Vaxcyte Merus Grifols (NASDAQ:GRFS) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, community ranking, risk, media sentiment and valuation. Which has more volatility & risk, GRFS or EWTX? Grifols has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Do analysts rate GRFS or EWTX? Edgewise Therapeutics has a consensus price target of $39.78, indicating a potential upside of 157.46%. Given Edgewise Therapeutics' higher probable upside, analysts plainly believe Edgewise Therapeutics is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Is GRFS or EWTX more profitable? Grifols' return on equity of 0.00% beat Edgewise Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A Edgewise Therapeutics N/A -26.83%-25.67% Does the MarketBeat Community believe in GRFS or EWTX? Grifols received 311 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. However, 73.21% of users gave Edgewise Therapeutics an outperform vote while only 56.23% of users gave Grifols an outperform vote. CompanyUnderperformOutperformGrifolsOutperform Votes35256.23% Underperform Votes27443.77% Edgewise TherapeuticsOutperform Votes4173.21% Underperform Votes1526.79% Does the media prefer GRFS or EWTX? In the previous week, Edgewise Therapeutics had 3 more articles in the media than Grifols. MarketBeat recorded 7 mentions for Edgewise Therapeutics and 4 mentions for Grifols. Grifols' average media sentiment score of 1.04 beat Edgewise Therapeutics' score of 0.86 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, GRFS or EWTX? Grifols has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.21B0.86$64.20M$1.177.71Edgewise TherapeuticsN/AN/A-$100.16M-$1.55-9.97 SummaryGrifols beats Edgewise Therapeutics on 11 of the 15 factors compared between the two stocks. Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EWTX vs. The Competition Export to ExcelMetricEdgewise TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.63B$6.83B$5.57B$8.67BDividend YieldN/A2.50%5.27%4.19%P/E Ratio-10.308.7927.2020.17Price / SalesN/A263.51412.92161.94Price / CashN/A65.8538.2534.64Price / Book3.416.677.114.72Net Income-$100.16M$143.49M$3.23B$247.80M7 Day Performance6.63%5.15%3.77%2.76%1 Month Performance5.97%15.43%13.33%9.71%1 Year Performance-9.65%6.02%32.03%14.51% Edgewise Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EWTXEdgewise Therapeutics3.1114 of 5 stars$15.45+1.2%$39.78+157.5%-9.8%$1.63BN/A-10.3060Positive NewsGRFSGrifols2.8944 of 5 stars$8.30-0.1%N/A+26.9%$5.71B$7.21B7.0926,300TLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.80-1.1%$22.00+31.0%N/A$5.68B$783.21M0.00N/APositive NewsTGTXTG Therapeutics3.0267 of 5 stars$35.75+1.8%$40.80+14.1%+148.0%$5.68B$386.39M-357.46290Positive NewsAnalyst RevisionNUVLNuvalent2.4966 of 5 stars$77.18+3.4%$115.50+49.7%-0.7%$5.54BN/A-22.2440Positive NewsLEGNLegend Biotech3.3398 of 5 stars$29.32+1.3%$76.20+159.9%-17.3%$5.39B$728.30M-30.861,070Analyst RevisionLNTHLantheus4.4356 of 5 stars$77.13+2.1%$132.67+72.0%+1.4%$5.34B$1.54B12.83700AXSMAxsome Therapeutics4.8517 of 5 stars$107.66+2.4%$172.14+59.9%+53.1%$5.30B$432.16M-17.97380Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionADMAADMA Biologics2.307 of 5 stars$20.43+3.0%$24.25+18.7%+99.0%$4.88B$459.38M72.96530Insider TradeAnalyst RevisionPCVXVaxcyte2.4698 of 5 stars$35.02+7.8%$136.50+289.8%-48.2%$4.52BN/A-7.61160MRUSMerus2.9562 of 5 stars$58.53+4.4%$86.00+46.9%+5.9%$4.05B$54.73M-14.8237High Trading Volume Related Companies and Tools Related Companies Grifols Competitors Telix Pharmaceuticals Limited American Depositary Shares Competitors TG Therapeutics Competitors Nuvalent Competitors Legend Biotech Competitors Lantheus Competitors Axsome Therapeutics Competitors ADMA Biologics Competitors Vaxcyte Competitors Merus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EWTX) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
